Display options
Cite
He J, Wang X, Guan H, et al. Clinical efficacy of local targeted chemotherapy for triple-negative breast cancer. Radiol Oncol. 2011;45(2):123-8doi: 10.2478/v10019-011-0014-7.
He, J., Wang, X., Guan, H., Chen, W., Wang, M., Wu, H., Wang, Z., Zhou, R., & Qiu, S. (2011). Clinical efficacy of local targeted chemotherapy for triple-negative breast cancer. Radiology and oncology, 45(2), 123-8. https://doi.org/10.2478/v10019-011-0014-7
He, Jinsong, et al. "Clinical efficacy of local targeted chemotherapy for triple-negative breast cancer." Radiology and oncology vol. 45,2 (2011): 123-8. doi: https://doi.org/10.2478/v10019-011-0014-7
He J, Wang X, Guan H, Chen W, Wang M, Wu H, Wang Z, Zhou R, Qiu S. Clinical efficacy of local targeted chemotherapy for triple-negative breast cancer. Radiol Oncol. 2011 Jun;45(2):123-8. doi: 10.2478/v10019-011-0014-7. Epub 2011 Apr 23. PMID: 22933945; PMCID: PMC3423732.
Copy Download .nbib Format: NLM
Share it on

Radiol Oncol. 2011 Jun;45(2):123-8. doi: 10.2478/v10019-011-0014-7. Epub 2011 Apr 23.

Clinical efficacy of local targeted chemotherapy for triple-negative breast cancer.

Radiology and oncology

Jinsong He, Xianming Wang, Hong Guan, Weicai Chen, Ming Wang, Huisheng Wu, Zun Wang, Ruming Zhou, Shuibo Qiu

Affiliations

  1. The Center of Diagnosis and Treat of Breast Disease, The Second People's Hospital of Shenzhen City, Shenzhen, P. R. China.

PMID: 22933945 PMCID: PMC3423732 DOI: 10.2478/v10019-011-0014-7

Abstract

BACKGROUND: The aim of the study was to evaluate the clinical efficacy of superselective intra-arterial targeted neo-adjuvant chemotherapy in the treatment of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor receptor 2 (HER2)-negative (triple-negative) breast cancer. PATIENTS AND METHODS.: A total of 47 triple-negative breast cancer patients (29 at stage II, 13 at stage III and 5 at stage IV) were randomly assigned to two groups: targeted chemotherapy group (n=24) and control group (n=23). Patients in the targeted chemotherapy group received preoperative superselective intra-arterial chemotherapy with CEF regimen (C: cyclophosphamide [600 mg/m(2)]; E: epirubicin [90 mg/m(2)]; F: 5-fluorouracil [600 mg/m(2)]), and those in the control group received routine neoadjuvant chemotherapy with CEF. The duration of the treatment, changes in lesions and the prognosis were determined.

RESULTS: The average course of the treatment was 15 days in the targeted chemotherapy group which was significantly shorter than that in the control group (31 days) (P<0.01). The remission rate of lesions was 91.6% in the targeted chemotherapy group and 60.9% in the control group, respectively. Among these patients, 9 died within two years, including 2 (both at IV stage) in the targeted chemotherapy group and 7 (2 at stage II, 4 at stage III and 1 at stage IV) in the control group.

CONCLUSIONS: As an neoadjuvant therapy, the superselective intra-arterial chemotherapy is effective for triple-negative breast cancer, with advantages of the short treatment course and favourable remission rates as well as prognoses.

Keywords: prognosis; targeted chemotherapy; triple-negative breast cancer

References

  1. Gan To Kagaku Ryoho. 2009 Nov;36(12):2108-10 - PubMed
  2. In Vivo. 2006 Nov-Dec;20(6A):761-4 - PubMed
  3. Clin Cancer Res. 2007 Apr 15;13(8):2329-34 - PubMed
  4. Cancer. 2007 May 1;109(9):1721-8 - PubMed
  5. Cancer Invest. 2010 Oct;28(8):878-83 - PubMed
  6. Mod Pathol. 2006 May;19(5):617-21 - PubMed
  7. Clin Cancer Res. 2010 Oct 1;16(19):4702-10 - PubMed
  8. N Engl J Med. 2010 Nov 11;363(20):1938-48 - PubMed
  9. Cancer. 2007 Jan 1;109(1):25-32 - PubMed
  10. Breast Cancer Res Treat. 2010 Nov;124(1):133-40 - PubMed
  11. Radiol Oncol. 2011 Mar;45(1):46-52 - PubMed
  12. Lancet Oncol. 2007 Mar;8(3):235-44 - PubMed
  13. BMC Cancer. 2010 Oct 05;10:527 - PubMed
  14. Eur J Radiol. 2002 Apr;42(1):1 - PubMed
  15. Cardiovasc Intervent Radiol. 2009 Sep;32(5):1059-66 - PubMed
  16. Ann Surg Oncol. 2010 Oct;17 Suppl 3:384-90 - PubMed

Publication Types